Bristol-Myers Squibb Co (NYSE:BMY)

65.67
Delayed Data
As of Mar 04
 +3.75 / +6.06%
Today’s Change
46.30
Today|||52-Week Range
65.92
+11.25%
Year-to-Date
Bristol-Myers Squibb Hits All-Time High Off FDA Approval For Expanded Use Of Opvido
Mar 04 / Benzinga
Bristol Myers Reports Data Supporting Clinical Development Of BMS-955176
Feb 26 / Benzinga
Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer
Mar 04 / TheStreet.com
The 3 Biggest Disappointments This Earnings Season
Feb 25 / MotleyFool.com
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Mar 04 / Zacks.com
Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog
Feb 24 / Zacks.com
Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Mar 04 / Zacks.com
Stock Market News for February 24, 2015 - Market News
Feb 24 / Zacks.com
Bristol-Myers Files for New Indications for Yervoy, Opdivo - Analyst Blog
Mar 03 / Zacks.com
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog
Feb 23 / Zacks.com
Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patien...
Mar 03 / Benzinga
Why Shares of Rigel Pharmaceuticals Inc. Exploded Today
Feb 23 / MotleyFool.com
3 Best Performing Stocks in February - Analyst Blog
Mar 02 / Zacks.com
Energy stocks retreat after crude declines
Feb 23 / FT.com
UPDATE: USDA Approves Supplimental Biologics License
Mar 02 / Benzinga
The $10 Billion Reason That This Tiny Biotech Stock Could Soar
Feb 22 / MotleyFool.com
USDA Accepts Supplemental Biologics License Application for Yervoy As Adjuvant Treatm...
Mar 02 / Benzinga
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Feb 19 / MotleyFool.com
Which Cancer Immunotherapy Will Be the Most Successful?
Feb 28 / MotleyFool.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account